Expert Ritu Salani, MD, MBA, reviews data from TROPiCS-03 and considers the potential role for antibody drug conjugates in patients with advanced endometrial cancer.
Ritu Salani, MD, MBA: I know we've talked a lot about immunotherapy, but the last thing I want to highlight is the use of sacituzumab govitecan in patients with metastatic solid tumors. This is phase 2 basket study, and it's known as TROPiCS-03. It is an early analysis in patients with advanced metastatic endometrial cancer and this study is really exciting. Sacituzumab, which we call Sassy, targets Trop-2 in tumors. This has been highly expressed in endometrial cancer, although there's some data that suggests that Trop-2 expression may not correlate with response rates. This is an antibody-drug conjugate that targets Trop-2. It's nice to have a nonimmunotherapy agent that's on the horizon as well.
What we're seeing with Sassy in this setting is some really impressive clinical response rates. The data is still early, but it may help inform practice and offer another therapy for our patients when they recur, even in the frontline setting if we can find biomarker-specific patients who may benefit the most from this.
Transcript edited for clarity.